scholarly journals Тhе genetic epidemiology of multiple sclerosis

2000 ◽  
Vol XXXII (1-2) ◽  
pp. 81-81
Author(s):  
A. Compston
Keyword(s):  
Multiple Sclerosis ◽  
Nervous System ◽  
Peripheral Nervous System ◽  
Genetic Epidemiology ◽  
Progressive Disease ◽  
Multiple Lesions ◽  
Chronic Progressive Disease

Multiple sclerosis is a chronic progressive disease of the nervous system, proceeding with exacerbations and remissions, or steadily progressively, with multiple lesions in the central and peripheral nervous system.

Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity

2018 ◽  
Vol 26 (2) ◽  
pp. 210-219 ◽  
Author(s):  
Heidi Högel ◽  
Eero Rissanen ◽  
Christian Barro ◽  
Markus Matilainen ◽  
Marjo Nylund ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Nervous System ◽  
Glial Fibrillary Acidic Protein ◽  
Disease Progression ◽  
Disease Severity ◽  
Single Molecule ◽  
Progressive Disease ◽  
Disease Duration ◽  
Acidic Protein ◽  
Csf Levels

Background: Cerebrospinal fluid (CSF) levels of two soluble biomarkers, glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL), have been shown to associate with multiple sclerosis (MS) disease progression. Now, both biomarkers can be detected reliably in serum, and importantly, their serum levels correlate well with their CSF levels. Objective: To evaluate the usability of serum GFAP measurement as a biomarker of progressive disease and disease severity in MS. Methods: Clinical course, Expanded Disability Status Scale (EDSS), disease duration, patient age and magnetic resonance imaging (MRI) parameters were reviewed in 79 MS patients in this cross-sectional hospital-based study. Serum samples were collected for measurement of GFAP and NfL concentrations using single molecule array (Simoa) assay. A cohort of healthy controls was evaluated for comparison. Results: Higher serum concentrations of both GFAP and NfL were associated with higher EDSS, older age, longer disease duration, progressive disease course and MRI pathology. Conclusion: Earlier studies have demonstrated that GFAP, unlike NfL, is not increased in association with acute focal inflammation-related nervous system damage. Our work suggests that GFAP serum level associates with disease progression in MS and could potentially serve as an easily measurable biomarker of central nervous system (CNS) pathology related to disease progression in MS.

Peripheral nervous system involvement in multiple sclerosis

Neurology ◽  
1991 ◽  
Vol 41 (3) ◽  
pp. 457-457 ◽  
Author(s):  
P. C. Zee ◽  
B. A. Cohen ◽  
T. Walczak ◽  
B. Jubelt
Keyword(s):  
Multiple Sclerosis ◽  
Nervous System ◽  
Peripheral Nervous System ◽  
System Involvement

Peripheral nervous system involvement in multiple sclerosis

2011 ◽  
Vol 18 (5) ◽  
pp. 789-791 ◽  
Author(s):  
K. Gartzen ◽  
Z. Katzarava ◽  
H.-C. Diener ◽  
N. Putzki
Keyword(s):  
Multiple Sclerosis ◽  
Nervous System ◽  
Peripheral Nervous System ◽  
System Involvement

scholarly journals The clinical manifestations of nervous system mesenchyme syphilis

2002 ◽  
Vol 1 (2) ◽  
pp. 77-82
Author(s):  
T. A. Valikova ◽  
V. M. Alifirova ◽  
I. M. Fyodorova ◽  
N. Yu. Paimursina
Keyword(s):  
Nervous System ◽  
Progressive Disease ◽  
Clinical Manifestations ◽  
Pathological Process ◽  
Acute Stage ◽  
Pathologic Process ◽  
First Case ◽  
Brain Substance ◽  
Chronic Progressive Disease ◽  
The Brain

Nervous system syphilis — neurosyphilis (NS) belongs to rather rare diseases. According to the different authors data available it comes to about 1% of the nervous system organic disturbances and develops by 5—10% syphilous patients not having been treated in the acute stage of the pathological process. The syphilitic disturbance of the nervous system is a chronic progressive disease caused by the pale spirochaeta. The nervous system disturbance occurs basically in two ways: secondary one, because of brain shells, vessels, gummatous manifestations involving in the pathologic process; or primary one, when the causative agent affects directly the brain substance. In the first case syphilis is called rnesodermic or early one; in the second case — parenchymatous or late, primary one. In the article the analysis of two clinical cases of mesenchyme neurosyphilis is carried out: latent neurosyphilis and syphilitic meningomyelitis. Neurosyphilis classification is applied to clinical manifestatons of syphilitic arachnoiditis and vasculitis are described. The methods of specific and nonspecific therapy of mesenchyme syphilis are stated in detail.

scholarly journals The effectiveness of physical factors used in the treatment of patients with Multiple Sclerosis. Literature review

2015 ◽  
Vol 29 (3) ◽  
pp. 35-42
Author(s):  
Jolanta Zwolińska ◽  
Andrzej Kwolek ◽  
Monika Gąsior
Keyword(s):  
Multiple Sclerosis ◽  
Progressive Disease ◽  
Physical Factors ◽  
Functional Capability ◽  
Physical Treatment ◽  
Fatal Disease ◽  
Current State ◽  
Chronic Progressive Disease ◽  
Physical Treatments ◽  
Selection Of

AbstractIntroduction: Multiple Sclerosis (MS) is a chronic progressive disease of the nervous system which etiology is still unknown. Environmental factors, genetic predisposition and complex autoimmune reactions play a significant role in its pathogenesis. MS is not a fatal disease, but patients often require constant medical care and complex social welfare. Physiotherapy conducted at every stage of the disease depends on the current state of a patient and their functional capability and gradually occurring disorders and dysfunctions. Physical therapy is an important element of the therapy.Aim: To evaluate the usefulness of physical treatments used in the treatment of the MS patients.Material and methods: An analysis of domestic and foreign literature published between 2004 and 2014. The following databases were searched: PubMed, Science Direct, Termedia, Polish Medical Bibliography, Cochrane. The papers concerning the use of physical treatment as monotherapy and combination therapy were included.Summary and conclusions: Numerous research confirm both safety and efficacy of physical methods used in treatment of the MS patients. The implementation of research on the mechanism of action and effectiveness of physical factors, which are well-designed in terms of methodology, allows for the selection of the optimal physical procedure. Modern equipment and current methods of physiotherapy change views on the previously used treatments, their methodology and application.

scholarly journals Blood and CSF Biomarker Dynamics in Multiple Sclerosis: Implications for Data Interpretation

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
M. J. Eikelenboom ◽  
B. M. J. Uitdehaag ◽  
A. Petzold
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Cerebrospinal Fluid ◽  
Nervous System ◽  
Peripheral Nervous System ◽  
Serum Levels ◽  
Disability Progression ◽  
Protein Biomarker ◽  
The Central Nervous System ◽  
Neuroaxonal Degeneration

Background. Disability in multiple sclerosis (MS) is related to neuroaxonal degeneration. A reliable blood biomarker for neuroaxonal degeneration is needed.Objectives. To explore the relationship between cerebrospinal fluid (CSF) and serum concentrations of a protein biomarker for neuroaxonal degeneration, the neurofilaments heavy chain (NfH).Methods. An exploratory cross-sectional (n=51) and longitudinal (n=34) study on cerebrospinal fluid (CSF) and serum NfH phosphoform levels in patients with MS. The expanded disability status scale (EDSS), CSF, and serum levels of NfH-SMI34 and NfH-SMI35 were quantified at baseline. Disability progression was assessed at 3-year followup.Results. At baseline, patients with primary progressive MS (PPMS, EDSS 6) and secondary progressive MS (SPMS, EDSS 6) were more disabled compared to patients with relapsing remitting MS (RRMS, EDSS 2,P<.0001). Serum and CSF NfH phosphoform levels were not correlated. Baseline serum levels of the NfH-SMI34 were significantly (P<.05) higher in patients with PPMS (2.05 ng/mL) compared to SPMS (0.03 ng/mL) and RRMS (1.56 ng/mL). In SPMS higher serum than CSF NfH-SMI34 levels predicted disability progression from baseline (ΔEDSS2,P<.05). In RRMS higher CSF than serum NfH-SMI35 levels predicted disability progression (ΔEDSS2,P<.05).Conclusion. Serum and CSF NfH-SMI34 and NfH-SMI35 levels did not correlate with each other in MS. The quantitative relationship of CSF and serum NfH levels suggests that neuroaxonal degeneration of the central nervous system is the likely cause for disability progression in RRMS. In more severely disabled patients with PP/SPMS, subtle pathology of the peripheral nervous system cannot be excluded as an alternative source for blood NfH levels. Therefore, the interpretation of blood protein biomarker data in diseases of the central nervous system (CNS) should consider the possibility that pathology of the peripheral nervous system (PNS) may influence the results.

‘ONION BULB’ FORMATIONS IN THE CENTRAL AND PERIPHERAL NERVOUS SYSTEM IN ASSOCIATION WITH MULTIPLE SCLEROSIS AND HYPERTROPHIC POLYNEUROPATHY

Brain ◽  
1977 ◽  
Vol 100 (4) ◽  
pp. 755-773 ◽  
Author(s):  
WILLIAM C. SCHOENE ◽  
STIRLING CARPENTER ◽  
PETER O. BEHAN ◽  
NORMAN GESCHWIND
Keyword(s):  
Multiple Sclerosis ◽  
Nervous System ◽  
Peripheral Nervous System ◽  
Onion Bulb
Sign in / Sign up

Export Citation Format

Share Document